Antibodies to type II collagen in SLE: A role in the pathogenesis of deforming arthritis?

Choi, Edward K. K.; Gatenby, Paul A.; Bateman, John F.; Cole, William G.

doi:10.1038/icb.1990.4

Cited by 15 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum autoantibodies against native and denatured type II collagen (anti-NCII and DCII) are detected in 24–30% of patients with RA, as shown by cross-sectional studies on patients with well-established disease [5-8]. However, this relatively low frequency in RA of anti-CII, together with seropositivity (albeit at even lower frequency) in other rheumatological and inflammatory diseases [7] including psoriatic arthritis (PsA) [7,9], osteoarthritis (OA) [7,10,11], juvenile arthritis [12], Paget's disease [10,11], and systemic lupus erythematosus [6,7,10,13], has negated the diagnostic utility and pathogenetic significance of anti-CII in RA. However, several studies have reported that the frequency of anti-NCII might be as high as 60–75% in patients with RA when tested very early in the disease [14-16], and thereafter frequencies tend to fall to those ascertained in the earlier cross-sectional studies [17], suggesting that their presence might provide a sensitive predictive marker for cases of early RA.…”

Section: Introductionmentioning

confidence: 99%

Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis

et al. 2004

View full text Add to dashboard Cite

Antibodies against intact type II collagen (CII) are a feature of rheumatoid arthritis (RA) but have limited diagnostic value. Here we assess whether either of the two major cyanogen bromide fragments of CII, namely CB10 or CB11, are more sensitive substrates for the detection of antibodies in RA. Cleavage of bovine CII with cyanogen bromide yielded CB10 and CB11; these were purified by column chromatography for use in an enzyme-linked immunosorbent assay. Serum antibodies were measured in patients with RA, psoriatic arthritis (PsA), osteoarthritis (OA) and blood donors. Results were compared with those using intact CII. Antibodies against CB10 were found in as many as 88% of 96 patients with long-standing RA, but only 12% of 33 patients with PsA, 6% of 34 patients with OA and 3% of 93 control sera. Lower frequencies for these diseases were obtained on testing for antibodies against CB11: 50%, 6%, 21% and 2%, respectively. The sensitivity of detection in RA of antibodies against CB10 compared with antibodies against intact CII (88% versus 24%) was not at the expense of specificity, which remained high at 94%. The much higher frequency of antibodies against CB10 in RA than in other rheumatic diseases or control sera indicates that CB10 is clearly a more sensitive substrate than the intact collagen molecule and, combined with other assays (rheumatoid factor, anti-cyclic citrullinated peptide [anti-CCP]), might comprise a panel with a highly reliable predictive value. Moreover, our findings should encourage renewed interest in the role of collagen autoimmunity in the pathogenesis of RA.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis

et al. 2004

View full text Add to dashboard Cite

show abstract

“…In view of this, as with lupus nephritis classification, we should adequately classify LA earlier to identify patients who have a more aggressive phenotype that resembles RA patients. The utilization of serological markers [17][18][19] and the use of joint US or MRI to identify patients with LA at risk of developing deforming arthritis are promising, but, until now, they are of little practical use and of low accessibility in the rheumatologist's office routine.…”

Section: Discussionmentioning

confidence: 99%

Clinical disease activity index applicability in lupus arthropathy: Unraveling underdiagnosed joint activity

Moura,

Fonseca,

Alves

et al. 2023

Lupus

View full text Add to dashboard Cite

Introduction Lupus arthropathy (LA) ranges from arthralgia and non-deforming arthritis to severe forms such as Jaccoud-type deformities and mutilating arthritis. Considering the evolving concept of LA, measuring arthritis activity in lupus patients may require a more practical and sensitive tool other than the classical composite scores. Methods In this cross-sectional study, we evaluated the articular pattern of a sample of SLE patients which were divided into those that scored in articular domain on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and those with activity arthritis using the Clinical Disease Activity Index (CDAI). After all, we analyzed the association between CDAI and arthritis by SLEDAI-2K as well as its association with the presence or not of Jaccoud-type arthropathy (JA). Results A total of 127 patients with SLE were evaluated. According to SLEDAI-2K, 17 (13.4%) patients have scored in its joint criteria and 32 patients (25.19%) were considered to have some articular activity by CDAI. A total of 16 patients (50%) who scored some activity on CDAI did not score in articular domain of SLEDAI-2K. Also, the presence of Jaccoud-type arthropathy was significantly associated with arthritis activity according to the CDAI score ( p = .014) but not with SLEDAI-2K joint criteria ( p = .524). Conclusion The CDAI was not directly associated with the presence of arthritis by the joint criteria of SLEDAI-2K and the presence of JA was significantly associated with the CDAI but not with arthritis at SLEDAI-2K.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several previous studies have attempted to associate JA with the presence of autoantibodies, such as anti-dsDNA, ACL, and type II anticollagen, but they showed conflicting results. [21][22][23] One study observed that the serum of patients with SLE and JA presents with higher levels of interleukin 6 (IL-6) than in those with SLE, but without JA. 24 Although it lacks sufficient specificity to be considered a biomarker for JA in SLE, increased IL-6 in this clinical setting may suggest that the use of biological molecules, such as tocilizumab (anti-IL-6), may have a place in the treatment of SLE and perhaps prevent the development of JA.…”

Section: Discussionmentioning

confidence: 99%

Videocapillaroscopic Findings in Patients With Systemic Lupus Erythematosus With or Without Jaccoud Arthropathy

et al. 2020

View full text Add to dashboard Cite

Background/Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease that can present changes in blood vessels, which can be evaluated by periungual nailfold videocapillaroscopy (VCP). This technique is important for the diagnosis of systemic sclerosis and to identify individuals with Raynaud phenomenon at higher risk of developing systemic sclerosis. This study aims to describe the videocapillaroscopic profile of a series of SLE patients and to investigate if the VCP pattern is different among those with Jaccoud arthropathy (JA) compared with those without.Methods: Between September 2014 and March 2015, the patients in this study underwent VCP, clinical evaluation, and laboratory tests. The capillaroscopic patterns were defined as minor, major, and scleroderma (SD). The presence of capillaroscopic findings, such as elongated capillaries, tortuosity, ectasia, prominent venous plexus, neoangiogenesis, hemorrhage, and megacapillaries, were also observed. Associations were calculated using the χ 2 , Fisher exact, or Student t test. Results:In a population of 113 females with SLE (67 without JA and 46 with JA), at least 1 alteration was observed in VCP in 89.40% of them, among which "nonspecific changes" were the most prevalent. Minor changes were seen in 39 (58.2%) and 26 (56.5%), major changes in 21 (31.3%) and 11 (23.9%), and SD pattern in 2 (3.0%) and 3 (6.5%), in the patients without and with JA, respectively (p > 0.05). Conclusions:The majority of patients with SLE demonstrated changes in the VCP examination, but this tool did not allow discrimination between those with or without JA.

show abstract

Antibodies to type II collagen in SLE: A role in the pathogenesis of deforming arthritis?

Cited by 15 publications

References 14 publications

Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis

Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis

Clinical disease activity index applicability in lupus arthropathy: Unraveling underdiagnosed joint activity

Videocapillaroscopic Findings in Patients With Systemic Lupus Erythematosus With or Without Jaccoud Arthropathy

Contact Info

Product

Resources

About